Grifols GIFLF
NASDAQ GIFLF
$11.08 +0.00 (+0.00%)
At close: Sep 8, 2026 · 4:00 PM EDT

Grifols (GIFLF) Long-Term Investments (2009 - 2025)

Grifols' (GIFLF) quarterly Long-Term Investments came in at $112.9 million in Q4 2025, up 53.14% on a YoY basis from $73.7 million in Q4 2024, and up 53.14% quarter-over-quarter from $73.7 million in Q4 2024.

Analysis

Grifols (GIFLF) Long-Term Investments (2009 - 2025) Analysis & Trends

Grifols (GIFLF) has reported Long-Term Investments for 17 consecutive years, with $112.9 million the latest figure, recorded in Q4 2025.

  • For the quarter ending Q4 2025, Long-Term Investments rose 53.14% year-over-year to $112.9 million; the trailing twelve-month figure through Dec 2025 stood at $112.9 million (up 53.14% YoY), and the FY2025 full-year result was $109.6 million, up 1726.53% from the prior year.
  • Long-Term Investments grew to $112.9 million in Q4 2025 per GIFLF's latest filing, from $73.7 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $1.8 billion in Q4 2021 and bottomed at $73.7 million in Q4 2024.
  • Historically, Long-Term Investments has averaged $786.5 million across 5 years, with a median of $453.0 million in 2023.
  • The sharpest annual moves came in 2024 and 2025: Long-Term Investments plunged 83.72% in 2024, then jumped 53.14% in 2025.
  • Over 5 years, Long-Term Investments stood at $1.8 billion in 2021, then slipped by 13.39% to $1.5 billion in 2022, then plunged by 70.36% to $453.0 million in 2023, then slumped by 83.72% to $73.7 million in 2024, then surged by 53.14% to $112.9 million in 2025.
  • According to Business Quant data, Long-Term Investments over the past three periods registered $112.9 million, $73.7 million, and $453.0 million for Q4 2025, Q4 2024, and Q4 2023 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Investments (Qtr)
1 Amgen 203.97 Bn 189.99 Bn 7.24 Bn -
2 Gilead Sciences 178.74 Bn 175.56 Bn 6.22 Bn -
3 Vertex Pharmaceuticals 130.73 Bn 122.88 Bn 2.84 Bn 5.79 Bn
4 Regeneron Pharmaceuticals 80.42 Bn 72.42 Bn 3.93 Bn 9.83 Bn
5 Argenx Se 60.40 Bn 55.21 Bn 1.37 Bn -4.00 Mn
6 Moderna 57.65 Bn 52.52 Bn 52.00 Mn 1.77 Bn
7 Alnylam Pharmaceuticals 33.37 Bn 30.07 Bn 992.69 Mn 22.17 Mn
8 Biogen 32.15 Bn 30.86 Bn 1.96 Bn -
9 Roivant Sciences 29.58 Bn 29.58 Bn 1.16 Mn -
10 Grifols 7.54 Bn 9.09 Bn 3.33 Bn 112.91 Mn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 112.91 Mn
Dec 31, 2024 73.73 Mn
Dec 31, 2023 452.97 Mn
Dec 31, 2022 1.53 Bn
Dec 31, 2021 1.76 Bn
Dec 31, 2020 2.23 Bn
Sep 30, 2020 2.19 Bn
Mar 31, 2020 2.11 Bn
Dec 31, 2019 126.71 Mn
Sep 30, 2019 138.01 Mn
Mar 31, 2019 269.66 Mn
Dec 31, 2018 258.99 Mn
Sep 30, 2018 261.93 Mn
Jun 30, 2018 269.46 Mn
Mar 31, 2018 271.47 Mn
Dec 31, 2017 257.87 Mn
Jun 30, 2017 245.73 Mn
Dec 31, 2016 217.40 Mn
Sep 30, 2016 220.93 Mn
Jun 30, 2016 228.70 Mn